BLACK DIAMOND

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 9, 2024
Diamond, FDA, Cancer, Foundation Medicine, Mutation, Investment, HGG, Food, Research, Lung cancer, GBM, Development, Administration, ASCO, TKI, Helmy Eltoukhy, BRAF, Patient, Society, G&A, AACR, Annual general meeting, Prevalence, NRAS, Pharmaceutical industry

Cash Position: Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023.

Key Points: 
  • Cash Position: Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023.
  • Net cash used in operations was $21.2 million for the first quarter of 2024 compared to $20.0 million for the first quarter of 2023.
  • Net Loss: Net loss for the first quarter of 2024 was $18.2 million, as compared to $20.9 million for the same period in 2023.
  • Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents and investments which the Company believes is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the third quarter of 2025.

Lactalis Canada Releases 2023 ESG Report

Retrieved on: 
Wednesday, May 8, 2024
Diamond, Cheese, Social, Intermodal transport, Safety, Policy, Lactalis, Animal welfare, Growth, Employment, Mental health, Astro, ESG, GHG, Caesars Entertainment, Cracker Barrel, Government, Community, Balderson, Organization, Blue cow, Climate

TORONTO, May 08, 2024 (GLOBE NEWSWIRE) -- Lactalis Canada –the Canadian dairy leader behind iconic brands like Cracker Barrel, Black Diamond, Balderson, Astro and Lactantia and a subsidiary of France-based Lactalis Group – today released Lactalis Canada’s 2023 Environmental, Social and Governance (ESG) Report which highlights the company’s commitment to being a sustainable and responsible dairy processor for its key stakeholders across its supply chain including its people, consumers, customers, suppliers, dairy farmers, government, industry and community partners.

Key Points: 
  • TORONTO, May 08, 2024 (GLOBE NEWSWIRE) -- Lactalis Canada –the Canadian dairy leader behind iconic brands like Cracker Barrel, Black Diamond, Balderson, Astro and Lactantia and a subsidiary of France-based Lactalis Group – today released Lactalis Canada’s 2023 Environmental, Social and Governance (ESG) Report which highlights the company’s commitment to being a sustainable and responsible dairy processor for its key stakeholders across its supply chain including its people, consumers, customers, suppliers, dairy farmers, government, industry and community partners.
  • “Our 2023 report highlights the tangible gains we have made in improving our performance towards our ESG goals,” said Mark Taylor, President & CEO, Lactalis Canada.
  • We know that by working more closely together, we can make faster and more meaningful progress.”
    This report details the company’s ESG achievements and advancements, as well as its future goals.
  • “We will maintain our high standards of profitable and responsible growth as we progress on our ESG journey, delivering value for all Lactalis Canada stakeholders.”

Black Diamond Group Limited Announces Renewal of Normal Course Issuer Bid

Retrieved on: 
Wednesday, May 8, 2024
Diamond, Toronto Stock Exchange, TSX, Calendar, BDI, Indian stock exchange, Security (finance)

CALGARY, Alberta, May 08, 2024 (GLOBE NEWSWIRE) -- Black Diamond Group Limited (TSX: BDI) (“Black Diamond” or the “Company”) announces that it has obtained approval of the Toronto Stock Exchange (the “TSX”) to renew its normal course issuer bid (the “NCIB”) with respect to its common shares (the “Common Shares”).

Key Points: 
  • CALGARY, Alberta, May 08, 2024 (GLOBE NEWSWIRE) -- Black Diamond Group Limited (TSX: BDI) (“Black Diamond” or the “Company”) announces that it has obtained approval of the Toronto Stock Exchange (the “TSX”) to renew its normal course issuer bid (the “NCIB”) with respect to its common shares (the “Common Shares”).
  • All Common Shares purchased by the Company under the NCIB will be cancelled.
  • Management of Black Diamond believes that, from time to time, the market price of the Common Shares may not fully reflect the underlying value of the Common Shares and that at such time the purchase of the Common Shares represents attractive investment value and would be in the best interests of Black Diamond.
  • The purchase of Common Shares by Black Diamond will increase the proportionate interest of, and be advantageous to, all remaining shareholders.

Black Diamond Reports First Quarter 2024 Results And Declares Dividend

Retrieved on: 
Friday, May 3, 2024
Diamond, TTM, Capital, MSS, News, Travel, TSX, Capital expenditure, WFS, Debt, BDI, Workforce, Quarter, Adjustment, Growth, Video game

CALGARY, Alberta, May 02, 2024 (GLOBE NEWSWIRE) -- Black Diamond Group Limited ("Black Diamond", the "Company" or "we"), (TSX:BDI), a leading provider of space rental and workforce accommodation solutions, today announced its operating and financial results for the three months ended March 31, 2024 (the "Quarter") compared with the three months ended March 31, 2023 (the "Comparative Quarter").

Key Points: 
  • CALGARY, Alberta, May 02, 2024 (GLOBE NEWSWIRE) -- Black Diamond Group Limited ("Black Diamond", the "Company" or "we"), (TSX:BDI), a leading provider of space rental and workforce accommodation solutions, today announced its operating and financial results for the three months ended March 31, 2024 (the "Quarter") compared with the three months ended March 31, 2023 (the "Comparative Quarter").
  • The Company’s consolidated contracted future rental revenue at the end of the Quarter grew 5% from the Comparative Quarter to $137.1 million.
  • LodgeLink net revenue of $2.6 million grew 18% from the Comparative Quarter on higher booking volumes than the Comparative Quarter.
  • Subsequent to the end of the Quarter, the Company declared a second quarter dividend of $0.03 payable on or about July 15, 2024 to shareholders of record on June 30, 2024.

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Diamond, Patient, Cancer, Glioblastoma, GBM, Pharmaceutical industry

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 ASCO Annual Meeting, taking place May 31 – June 4 in Chicago, IL.

Key Points: 
  • CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 ASCO Annual Meeting, taking place May 31 – June 4 in Chicago, IL.
  • The two poster presentations describe data for BDTX-1535 in patients with recurrent glioblastoma (GBM) across two clinical trials: a Phase 1 dose escalation trial, for which topline data were released in December 2023 , and a Phase 0/1 “trigger” (“window of opportunity”) trial conducted as an Investigator Sponsored Trial at the Ivy Brain Tumor Center ( NCT06072586 ).
  • Presentation details are as follows:
    Title: Phase 1 Study of BDTX-1535, an Oral 4th Generation Covalent EGFR Inhibitor, in Patients with Recurrent Glioblastoma: Preliminary Dose Escalation Results
    Posters will become available on June 1, 2024 at 10:00 AM EDT on the Black Diamond Therapeutics website here .

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Retrieved on: 
Monday, April 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Diamond, UBS, University, J.P. Morgan & Co., Dravet syndrome, Business administration, Columbia University, IPO, Bachelor of Economics, CPA, Patient, Initial public offering, MBA, Therapy, Economics, Growth

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer.
  • Mr. Leggett succeeds Stephen Tulipano, CPA, MBA, who resigned his position as Stoke’s Chief Financial Officer effective Tuesday, May 7.
  • Prior to joining Stoke, Mr. Leggett served as Chief Financial Officer at Affinia Therapeutics.
  • Before joining Affinia Therapeutics, Mr. Leggett was Chief Financial Officer at Black Diamond Therapeutics, where he led the Company’s $85 million Series C financing and $231 million IPO.

Black Diamond Therapeutics Announces Changes to Board of Directors

Retrieved on: 
Thursday, April 11, 2024
Diamond, Bayer, University, Executive, Ithaca College, University of Pennsylvania, Flagship Pioneering, Scripps Research, Pharmacia, Harvard Business School, Novartis, Therapy, Abbott Laboratories, IMD, Patient, Medicinal chemistry, Immunology, Takeda Oncology, EGFR, Cancer, NSCLC, Partnership, Management

The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors.

Key Points: 
  • The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors.
  • “On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncology expertise to our board as we advance BDTX-1535, a potential first and best-in-class fourth-generation EGFR inhibitor,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer of Black Diamond Therapeutics.
  • He currently serves as Chief Executive Officer of a stealth biopharma company working on novel protein therapeutics in Oncology and Immunology.
  • Previously, he was President and Chief Executive Officer of Ribon Therapeutics, a biopharmaceutical company focused on small molecule drugs for Oncology and Immunology.

THE PICKLR ANNOUNCES 2,760 NEW COURTS IN UNITED STATES AS IT LOOKS TO EXPAND INTERNATIONALLY

Retrieved on: 
Thursday, April 18, 2024
Real estate, Carvana, Super Bowl, Human resources, Marketing, Partnership, Growth, Super Bowl LVIII, Female, European, Senior, PPA

KAYSVILLE, Utah, April 18, 2024 /PRNewswire/ -- The Picklr, North America's fastest-growing indoor pickleball franchise, announced 276 total units sold to 36 unique direct franchising groups, which amounts to approximately 2,760 indoor courts, as they closed Q1 of 2024. More importantly, their extensively qualified franchising groups will be developing all of these units themselves over the next few years. In addition, 38 new clubs will open across the United States in 23 states, with 52 additional leases in final negotiations for openings in 2024 and 2025.

Key Points: 
  • More importantly, their extensively qualified franchising groups will be developing all of these units themselves over the next few years.
  • In addition, 38 new clubs will open across the United States in 23 states, with 52 additional leases in final negotiations for openings in 2024 and 2025.
  • The partnership aligns two of the largest brands in pickleball and will drive franchise growth and new memberships at Picklr locations.
  • "We are so pleased with our Q1 results, and as we push into Q2, we look forward to opening new clubs around the country."

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Retrieved on: 
Sunday, April 7, 2024
Diamond, EGFR, Helmy Eltoukhy, Mutation, Prevalence, NSCLC, Survival, Foundation Medicine, Patient, Cancer, Lung cancer, AACR, PACC, TKI, Drug resistance, MD Anderson Cancer Center, Associate professor

CAMBRIDGE, Mass., April 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (EGFR) mutation landscape in non-small cell lung cancer (NSCLC), and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.

Key Points: 
  • The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.
  • The analyses reveal a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S.
  • The compound also potently inhibits the drug resistance C797S mutation, which emerges following treatment with third-generation EGFR inhibitors, including osimertinib.
  • Black Diamond is currently advancing BDTX-1535 in a Phase 2 trial for patients with EGFRm NSCLC across multiple lines of therapy.

Birmingham, Alabama-Based Fairvoy Private Wealth Goes Independent with Dynasty Financial Partners

Retrieved on: 
Tuesday, April 9, 2024
Personal Finance, Technology, Finance, Fintech, Consulting, Banking, Professional Services, Software, Digital Cash Management, Digital Assets, Asset Management, Diamond, Partner (business rank), Merrill (company), Research, Fidelity, Dynasty, Financial adviser

Dynasty Financial Partners today announced that Fairvoy Private Wealth has joined its industry-leading platform of technology-driven wealth management tools and services.

Key Points: 
  • Dynasty Financial Partners today announced that Fairvoy Private Wealth has joined its industry-leading platform of technology-driven wealth management tools and services.
  • Fairvoy Private Wealth is an independent wealth management firm based in Birmingham, Ala., staffed by professionals from Merrill Lynch, including:
    Stephen Davis, CFP®, ChFC®, APMA®, Managing Partner, Senior Private Wealth Advisor
    Neal Carroll, CFP®, CPWA®, CPFA®, Chief Operating Officer, Senior Private Wealth Advisor
    Ashley Davis, CPA®, CRPC®, Chief Financial Officer, Senior Private Wealth Advisor
    The name "Fairvoy" invokes the firm's dedication to fairness and upholding its clients’ best interests on their wealth-management voyages.
  • “We are pleased to welcome the Fairvoy team to our Dynasty family and thrilled to include a new firm in the growing Birmingham market," said Shirl Penney, CEO and Founder of Dynasty Financial Partners.
  • Fairvoy has selected Fidelity as its custodian, Black Diamond for performance reporting, and eMoney Advisor for financial planning.